Related Experiment Video
Updated: Nov 2, 2025
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches
Samira Sanami1, Fatemeh Azadegan-Dehkordi2, Mahmoud Rafieian-Kopaei3
1Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Abstract:
Cervical cancer, caused by human papillomavirus (HPV), is the fourth most common type of cancer among women worldwide. While HPV prophylactic vaccines are available, they have no therapeutic effects and do not clear up existing infections. This study aims to design a therapeutic vaccine against cervical cancer using reverse vaccinology. In this study, the E6 and E7 oncoproteins from HPV16 were chosen as the target antigens for epitope prediction. Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (HTL) epitopes were predicted, and the best epitopes were selected based on antigenicity, allergenicity, and toxicity. The final vaccine construct was composed of the selected epitopes, along with the appropriate adjuvant and linkers. The multi-epitope vaccine was evaluated in terms of physicochemical properties, antigenicity, and allergenicity. The tertiary structure of the vaccine construct was predicted. Furthermore, several analyses were also carried out, including molecular docking, molecular dynamics (MD) simulation, and in silico cloning of the vaccine construct. The results showed that the final proposed vaccine could be considered an effective therapeutic vaccine for HPV; however, in vitro and in vivo experiments are required to validate the efficacy of this vaccine candidate.
Insights
This study designed a novel therapeutic vaccine for cervical cancer using reverse vaccinology targeting human papillomavirus (HPV). Computational analyses suggest its potential efficacy, pending further experimental validation.
Area of Science:
- Oncology
- Immunology
- Bioinformatics
Background:
- Cervical cancer is a major global health issue, primarily caused by human papillomavirus (HPV).
- Current HPV prophylactic vaccines do not treat existing infections or cancer.
- There is a need for effective therapeutic strategies against HPV-induced cervical cancer.
Purpose of the Study:
- To design a multi-epitope therapeutic vaccine against HPV using reverse vaccinology.
- To identify and select optimal T-cell epitopes from HPV16 E6 and E7 oncoproteins.
- To computationally evaluate the vaccine construct's properties and potential efficacy.
Main Methods:
- Reverse vaccinology approach for epitope prediction and selection.
- Antigenicity, allergenicity, and toxicity assessments of predicted epitopes.
- In silico construction, physicochemical evaluation, structural prediction, molecular docking, MD simulations, and cloning of the vaccine candidate.
Main Results:
- Selected cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) epitopes with favorable properties.
- Developed a multi-epitope vaccine construct with an adjuvant and linkers.
- Computational analyses including molecular docking and MD simulations indicated potential efficacy.
Conclusions:
- The designed multi-epitope vaccine is a promising therapeutic candidate for HPV-associated cervical cancer.
- Further in vitro and in vivo studies are necessary to confirm the vaccine's efficacy and safety.
